These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27388147)

  • 41. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
    Kusumoto S; Tanaka Y; Ueda R; Mizokami M
    J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].
    Gutiérrez García ML; Alonso Lopez S; Martín Rios MD; Sanmartin Fenollera P; Agudo Fernandez S; Fernández Rodriguez CM
    Gastroenterol Hepatol; 2015 Jan; 38(1):1-6. PubMed ID: 25205080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?
    Drößler L; Lehmann C; Töpelt K; Nierhoff D; Vehreschild JJ; Rybniker J; Hallek M; Fischer J; Stormberg V; Fätkenheuer G; Wieland U; Jung N
    Infection; 2019 Apr; 47(2):293-300. PubMed ID: 30689161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
    World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
    Rodríguez-Tajes S; Miralpeix A; Costa J; López-Suñé E; Laguno M; Pocurull A; Lens S; Mariño Z; Forns X
    J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
    Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
    Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
    Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
    Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
    Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country.
    Brakenhoff SM; Hoekstra R; Honkoop P; Roomer R; den Hollander JG; Bezemer G; de Knegt RJ; Sonneveld MJ; de Man RA
    Eur J Intern Med; 2023 Feb; 108():68-73. PubMed ID: 36462966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients.
    Kim J; Chung SJ; Sinn DH; Lee KW; Park JB; Huh W; Lee JE; Jang HR; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    J Viral Hepat; 2020 Jul; 27(7):739-746. PubMed ID: 32057171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
    Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
    Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure.
    Wong GL; Wong VW; Yuen BW; Tse YK; Yip TC; Luk HW; Lui GC; Chan HL
    J Hepatol; 2020 Jan; 72(1):57-66. PubMed ID: 31499132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
    Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
    Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
    Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
    Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.